Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors

Inclusion Criteria

• •Diagnosis: patients with recurrent/refractory medulloblastoma (MB), atypical teratoid (AT)/rhabdoid tumors (RT) or ependymoma involving the brain and/or spine at original diagnosis or relapse; they must have histological verification at diagnosis and/or relapse; patient must have presented with these tumors in the posterior fossa (PF) or relapsed in the PF
• •Patient must have either measurable or evaluable tumor
• •Presence of or determined by neurosurgery to be a candidate for an implanted catheter in the ventricles to receive NK cell infusion
• •Life expectancy of at least 12 weeks in opinion of principal investigator (PI) and/or designee
• •Lansky score of 50 or greater if =\<16 years of age or a Karnofsky score of 50 or greater if \> 16 years of age (NOTE: patients who are unable to walk because of paralysis, but who are in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score)
• •Neurologic deficits must have been relatively stable for a minimum of 1 week prior to study enrollment
• •Patients must have recovered from the acute toxic effects of all prior anticancer chemotherapy
• •Patient must be 4 weeks off any palliative radiation or craniospinal radiation
• •Absolute neutrophil count (ANC) of \>= 1000/uL
• •Platelet count of \>= 30,000
• •Hemoglobin of \>= 9.0 g/dl
• •Patients with a seizure disorder may be enrolled if well-controlled and on non-enzyme inducing anticonvulsants
• •Patient or patient's legal representative, parent(s), or guardian able to provide written informed consent